A team from Singapore’s A*STAR's Institute of Chemical and Engineering Sciences (ICES) and the National University Hospital (NUH) has discovered new ways to enhance the efficacy of drugs used to treat respiratory system infections and antibiotic-resistant superbugs.
The team, led by Desmond Heng of the ICES, has developed a new combination of drugs to effectively combat bacteria in the lungs which lead to common respiratory system infections, or bacteria-linked pulmonary diseases such as pneumonia, bronchiectasis and cystic fibrosis.
An acute upper respiratory tract infection, which includes the common flu, was reported to be among the top four conditions diagnosed at polyclinics for eight consecutive years, from 2006 to 2013. Pneumonia on the other hand, was the second leading cause of death in 2012, contributing to 16.8 per cent of the total number of deaths from illnesses behind cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze